FABHALTA®
(iptacopan) 200 mg capsules

IN C3G, FABHALTA CAN HELP YOU GO FORWARD

Patient portrayal.

The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria.

C3G, complement 3 glomerulopathy.

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).

It is not known if FABHALTA is safe and effective in children with C3G.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria,** including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

AN ULTRA-RARE DISEASE LIKE C3G CAN LEAD TO A DIFFICULT JOURNEY

It may have been frustrating to not have an approved treatment option for C3G

You've followed your doctor's recommendation so far, but you may want a therapy that's specific for your disease

Fortunately, there's a way for you to fight back against C3G

FABHALTA: THE FIRST AND ONLY FDA-APPROVED ORAL TREATMENT FOR ADULTS WITH C3G, TO REDUCE PROTEINURIA (PROTEIN IN THE URINE)

FABHALTA® (iptacopan) 200 mg capsules

Act now and ask your doctor about FABHALTA today!



Patient portrayal.

"Previously, there has not been something specific for C3G."

— Real C3G patient

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria,** including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.
  - You must complete or update your vaccinations against *Streptococcus pneumoniae* and *Neisseria meningitidis* at least 2 weeks before your first dose of FABHALTA.
  - If you have not completed your vaccinations and FABHALTA must be started right away, you should receive the required vaccinations as soon as possible.
  - If you have not been vaccinated and FABHALTA must be started right away, you should also receive antibiotics to take for as long as your health care provider tells you.
  - If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

Patient portrayal.

TRANSFORM THE WAY YOU REDUCE PROTEINURIA IN C3G WITH FABHALTA

The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria

An oral option that can fit into your daily routine

TAKE THE NEXT STEP IN YOUR JOURNEY WITH FABHALTA

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria,** including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.
  - Vaccines do not prevent all infections caused by encapsulated bacteria. **Call your health care provider or get emergency medical care right away if you have any of these signs and symptoms of a serious infection:**
    - Fever with or without shivers or chills
    - Fever with chest pain and cough
    - Fever with high heart rate
    - Headache and fever
    - Confusion
    - Clammy skin
    - Fever and rash
    - Fever with breathlessness or fast breathing
    - Headache with nausea or vomiting
    - Headache with stiff neck or stiff back
    - Body aches with flu-like symptoms
    - Eyes sensitive to light

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

FABHALTA: A FIRST-OF-ITS-KIND TARGETED C3G TREATMENT

FABHALTA is the first and only FDA-approved oral complement 3 glomerulopathy (C3G) treatment that targets the complement system. FABHALTA is a treatment for adults with C3G to reduce proteinuria.

In C3G, the complement system (a part of your immune system that helps fight infections) becomes overactive, resulting in a buildup of C3 in your kidneys as well as inflammation.



Kidney With C3G

Overactivation of the complement system results in a buildup of C3 deposits and inflammation



FABHALTA in Action in a Kidney With C3G

FABHALTA helps block a part of the complement system

Important Safety Information (continued)

What is the most important information I should know about FABHALTA? (continued)

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

FABHALTA CLINICAL STUDY OVERVIEW

The APPEAR-C3G trial for adults with C3G who had never received a kidney transplant studied the percentage reduction in urine protein-to-creatinine ratio, or UPCR, a test used to measure protein in urine. In this study, urine samples were collected over 24 hours, with results from the start of the study compared against those after 6 months.
Safety and effectiveness of FABHALTA in patients with C3G following kidney transplant have not been established.

What was studied? (Primary Study Objective)

The **reduction in UPCR**, a test used to measure protein in urine (proteinuria), after 6 months of treatment with FABHALTA or placebo.

Who was studied?

74 adults with biopsy-confirmed C3G who had never received a kidney transplant

- All patients had elevated proteinuria (UPCR ≥1.0 g/g) and eGFR ≥30 mL/min/1.73 m^2 at the start of the study, never had a kidney transplant, and were receiving a stable dose of maximally tolerated blood pressure medications (ACEi/ARB) with or without other background therapies 90 days prior to starting the study and throughout the study

How was the study done?

- For the first 6 months, 38 people received FABHALTA 200 mg twice daily and 36 people received placebo (sugar pill) twice daily
- During the next 6 months (extension period), all participants took FABHALTA 200 mg twice daily

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; eGFR, estimated glomerular filtration rate.

Important Safety Information (continued)

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program.
- Counsel you about the risk of serious infections caused by certain bacteria.
- Give you information about the symptoms of serious infections.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

Patient portrayal.

FABHALTA® (iptacopan) 200 mg capsules

Primary Study Objective
Change in Proteinuria at 6 Months



FABHALTA SUBSTANTIALLY REDUCED PROTEINURIA COMPARED TO PLACEBO AT 6 MONTHS

DID YOU KNOW?
Patient portrayal.

Increasing levels of proteinuria over time is an important indicator that your C3G may be getting worse.

Ask your doctor how FABHALTA can help reduce proteinuria.

Important Safety Information (continued)

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must: (continued)

- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start FABHALTA right away and you are not up-to-date on your vaccinations.
- Give you a **Patient Safety Card** about your risk of serious infections.

Who should NOT take FABHALTA?

Do not take FABHALTA if you:

- Are allergic to FABHALTA or any of the ingredients in FABHALTA.
- Have a serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type b, when you are starting FABHALTA.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

WITH FABHALTA, PROTEINURIA REDUCTION AT MONTH 6 WAS SUSTAINED THROUGH MONTH 12

Percentage Change in UPCR (g/g) From Baseline Over 12 Months



UPCR, urine protein-to-creatinine ratio.

In the study, a different measurement was taken to measure protein in the urine (proteinuria) called first morning void (FMV). FMV refers to the first urination of the day after you wake up and is more concentrated at this time.

- Although there was a numerical improvement at Month 6 between FABHALTA and placebo (sugar pill) in the reduction of proteinuria measured by FMV, this may not be attributable to FABHALTA alone and could be due to chance.

Important Safety Information (continued)

Before you take FABHALTA, tell your health care provider about all your medical conditions, including if you:

- Have an infection or fever.
- Have liver problems.
- Are pregnant or plan to become pregnant. It is not known if FABHALTA will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if FABHALTA passes into your breast milk. You should not breastfeed during treatment and for 5 days after your final dose of FABHALTA.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

SAFETY PROFILE OF FABHALTA

The most common side effects of FABHALTA in adults include:

- Headache
- Nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis)
- Diarrhea
- Pain in the stomach (abdomen)
- Infections (bacterial and viral)
- Nausea
- Rash

Because of the risk of serious infections, FABHALTA is only available through a Risk Evaluation and Mitigation Strategy (REMS) program that requires vaccinations.

See pages 9-10 for more information on the risk of serious infections and the need for vaccinations.

See page 11 for more on the FABHALTA REMS program.

FABHALTA may cause serious side effects, including increased cholesterol and triglyceride (lipid) levels in your blood.
Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA.
Your health care provider may start you on a medicine to lower your cholesterol if needed.

Tell your health care provider about any side effect that bothers you or that does not go away. These are not all of the possible side effects of FABHALTA.

Important Safety Information (continued)

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects.
Know the medicines you take and the vaccines you receive. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

VACCINATIONS NEEDED BEFORE STARTING FABHALTA

What is the most important information I should know about FABHALTA?

FABHALTA affects part of your immune system and may lower your ability to fight infections.

Certain vaccinations help protect you from the risk of serious infections while you are taking FABHALTA.

FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria, including *Streptococcus pneumoniae* (pneumonia), *Neisseria meningitidis* (meningitis), and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.

You must complete or update your vaccinations against *Streptococcus pneumoniae* and *Neisseria meningitidis* at least 2 weeks before starting FABHALTA.

If you have completed your required vaccinations and 2 weeks have passed, you can begin FABHALTA right away.*

If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.

*Some vaccines may require more than 1 dose, so it's important to know how many doses you need for each vaccine.

For more information about vaccination requirements, tips, and a vaccination checklist, please visit www.fabhalta.com/c3g/getting-started.

Vaccines do not prevent all infections caused by encapsulated bacteria.

Call your health care provider or get emergency medical care right away if you have any of these signs and symptoms of a serious infection:

- Fever with or without shivers or chills
- Fever with chest pain and cough
- Fever with high heart rate
- Headache and fever
- Confusion
- Clammy skin
- Fever and rash
- Fever with breathlessness or fast breathing
- Headache with nausea or vomiting
- Headache with stiff neck or stiff back
- Body aches with flu-like symptoms
- Eyes sensitive to light

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

IF YOU HAVE NOT COMPLETED YOUR REQUIRED VACCINATIONS, YOU HAVE 2 OPTIONS

OPTION 1

If you have not completed or updated your vaccinations before starting FABHALTA:

1. Complete or update your required vaccinations
2. Wait at least 2 weeks
3. Begin treatment with FABHALTA

OPTION 2

If FABHALTA needs to be started right away, but you haven't completed or updated your vaccinations, you should:

1. Begin treatment with FABHALTA and antibiotics. You will take these antibiotics for as long as your health care provider tells you
2. Continue to complete or update required vaccinations as soon as possible

While taking FABHALTA, you should be revaccinated according to current medical guidelines for encapsulated bacteria. Your health care provider or Novartis Patient Support can help you locate vaccinations.

The most common side effects of FABHALTA in adults include: headache; nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis); diarrhea; pain in the stomach (abdomen); infections (bacterial and viral); nausea; rash.

Tell your health care provider about any side effect that bothers you or that does not go away. These are not all of the possible side effects of FABHALTA.

Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How can I get help obtaining my vaccinations?

Your care team is your best source of information. Still have questions? Novartis Patient Support (NPS) can help you locate vaccination centers and offer other assistance along the way. For more on NPS, see pages 15-16.

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

THE FABHALTA REMS PROGRAM

Because of the risk of serious infection that comes with taking FABHALTA, it is only available through a restricted program called a Risk Evaluation and Mitigation Strategy (REMS)

Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program
- Counsel you about the risk of serious infections caused by certain bacteria
- Give you information about the symptoms of serious infections
- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start FABHALTA right away and you are not up to date on your vaccinations
- Give you a **Patient Safety Card** about your risk of serious infections, as discussed below

The FABHALTA Patient Safety Card

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry this card with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

If you notice any signs or symptoms described on this card, contact your doctor or get emergency medical assistance immediately.

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

APPROVED USE AND IMPORTANT SAFETY INFORMATION FOR FABHALTA (iptacopan)

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).

It is not known if FABHALTA is safe and effective in children with C3G.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria,** including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.
  - You must complete or update your vaccinations against *Streptococcus pneumoniae* and *Neisseria meningitidis* at least 2 weeks before your first dose of FABHALTA.
  - If you have not completed your vaccinations and FABHALTA must be started right away, you should receive the required vaccinations as soon as possible.
  - If you have not been vaccinated and FABHALTA must be started right away, you should also receive antibiotics to take for as long as your health care provider tells you.
  - If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting FABHALTA. Your health care provider will decide if you need additional vaccinations.
  - Vaccines do not prevent all infections caused by encapsulated bacteria. **Call your health care provider or get emergency medical care right away if you have any of these signs and symptoms of a serious infection:**
    - Fever with or without shivers or chills
    - Fever with chest pain and cough
    - Fever with high heart rate
    - Headache and fever
    - Confusion
    - Clammy skin
    - Fever and rash
    - Fever with breathlessness or fast breathing
    - Headache with nausea or vomiting
    - Headache with stiff neck or stiff back
    - Body aches with flu-like symptoms
    - Eyes sensitive to light

Your health care provider will give you a Patient Safety Card about the risk of serious infections. Carry it with you at all times during treatment and for 2 weeks after your last dose of FABHALTA. Your risk of serious infections may continue for a few weeks after your last dose of FABHALTA. It is important to show this card to any health care provider who treats you. This will help them diagnose and treat you quickly.

Please see additional Important Safety Information throughout and on page 13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

APPROVED USE AND IMPORTANT SAFETY INFORMATION FOR FABHALTA (iptacopan) (continued)

Important Safety Information (continued)

FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before you can take FABHALTA, your health care provider must:

- Enroll in the FABHALTA REMS program.
- Counsel you about the risk of serious infections caused by certain bacteria.
- Give you information about the symptoms of serious infections.
- Make sure that you are vaccinated against serious infections caused by encapsulated bacteria and that you receive antibiotics if you need to start FABHALTA right away and you are not up-to-date on your vaccinations.
- Give you a **Patient Safety Card** about your risk of serious infections.

Who should NOT take FABHALTA?

Do not take FABHALTA if you:

- Are allergic to FABHALTA or any of the ingredients in FABHALTA.
- Have a serious infection caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, or *Haemophilus influenzae* type b, when you are starting FABHALTA.

Before you take FABHALTA, tell your health care provider about all your medical conditions, including if you:

- Have an infection or fever.
- Have liver problems.
- Are pregnant or plan to become pregnant. It is not known if FABHALTA will harm your unborn baby.
- Are breastfeeding or plan to breastfeed. It is not known if FABHALTA passes into your breast milk. You should not breastfeed during treatment and for 5 days after your final dose of FABHALTA.

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects.

Know the medicines you take and the vaccines you receive. Keep a list of them to show your health care provider and pharmacist when you get a new medicine.

What are the possible side effects of FABHALTA?

FABHALTA may cause serious side effects, including:

- See **"What is the most important information I should know about FABHALTA?"**
- **Increased cholesterol and triglyceride (lipid) levels in your blood.** Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA. Your health care provider may start you on a medicine to lower your cholesterol if needed.

The most common side effects of FABHALTA in adults include:

- Headache
- Nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis)
- Diarrhea
- Pain in the stomach (abdomen)
- Infections (bacterial and viral)
- Nausea
- Rash

Tell your health care provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of FABHALTA.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and on page 12, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA CAN FIT INTO YOUR DAILY ROUTINE

1 capsule. Twice a day.

- Each capsule contains 200 mg
- Take 1 capsule twice a day with or without food
- Swallow the capsules whole
- **Do not** open, break, or chew capsules
- No refrigeration requirement*

What to do if you miss a dose or doses

If a dose or doses are missed, take one dose of FABHALTA as soon as you remember, even if it is almost time to take your next scheduled dose, and then take your next dose at your regularly scheduled time.

Take FABHALTA exactly as your doctor tells you. Do not change the dose or stop taking FABHALTA unless your doctor tells you.

*Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C and 30 °C (59 °F and 86 °F).


Patient portrayal.

Important Safety Information (continued)

What are the possible side effects of FABHALTA?

FABHALTA may cause serious side effects, including:

- See **"What is the most important information I should know about FABHALTA?"**
- **Increased cholesterol and triglyceride (lipid) levels in your blood.** Your health care provider will do blood tests to check your cholesterol and triglycerides during treatment with FABHALTA. Your health care provider may start you on a medicine to lower your cholesterol if needed.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

NOVARTIS PATIENT SUPPORT CAN HELP YOU EVERY STEP OF THE WAY

Personalized support that can help you start, stay, and save on treatment

Once you and your health care provider decide to begin FABHALTA, you can sign up or designate a loved one to sign you up for Novartis Patient Support. It's personalized support that can help you start, stay, and save on treatment.

Now, you have a dedicated team in your corner to help with:

Insurance Support
Navigate the insurance process and understand your insurance coverage information.

Financial Support
Learn about savings and other possible ways to afford your treatment.

Vaccination Support‡
Your dedicated Novartis Patient Support team can help you locate vaccinations.

Ongoing Support
Get helpful resources and answers to your questions throughout your treatment.

FINANCIAL SUPPORT

Learn about the $0 Co-Pay Plus* offer and FABHALTA Bridge Program† on the next page. Also see terms and conditions indicated with footnote symbols on the next page.

Sign up for Novartis Patient Support

1. **Call 1-833-99FABHA (1-833-993-2242)**, Monday-Friday, 8:00 AM-8:00 PM ET, excluding holidays. Your dedicated Novartis Patient Support team can then help you sign up

There are a few different ways to start getting support:

2. Sign up online by visiting **support.FABHALTA.com**
3. **Ask your health care provider** to help sign you up at your next appointment

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

NOVARTIS PATIENT SUPPORT TERMS AND CONDITIONS

Novartis Patient Support™

$0 Co-Pay Plus* offer

If you have private insurance, you may be eligible for the $0 Co-Pay Plus offer for FABHALTA through Novartis Patient Support.

FABHALTA Bridge Program†

If you have private or commercial insurance, the FABHALTA Bridge Program offers up to 12 months of FABHALTA for free while we work with your health care provider and health insurance to help get your medication covered.

To enroll in Co-Pay Plus*, scan the QR code or call 1-833-99FABHA (1-833-993-2242).

***Co-Pay Plus:** Limitations apply. Patients with commercial insurance coverage for FABHALTA may receive up to $20,000 in annual co-pay benefits for the cost of FABHALTA and up to $1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the program. Valid only in the United States, Puerto Rico and select territories. Void where prohibited by law. Additional restrictions may apply. This program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice.

†**Bridge Program:** Limitations apply. Patients with commercial insurance, a valid prescription for FABHALTA, and a denial of insurance coverage based on a prior authorization requirement may receive a monthly dose for up to 12 months or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state program, or where prohibited by law. A prior authorization and/or appeal of coverage denial must be submitted within 90 days to remain in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional restrictions may apply. Novartis reserves the right to rescind, revoke or amend this Program without notice.

‡**Vaccination support:** Limitations apply. Please contact Novartis Patient Support at 1-833-99FABHA (1-833-993-2242) for more information.

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

Patient
portrayal.

"I think not being afraid to ask for help would be the most important part. Give yourself grace and breathe through the changes."

— Real C3G patient

Please see Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

FABHALTA® (iptacopan) 200 mg capsules

TAKE THE NEXT STEP IN YOUR C3G JOURNEY

The first and only FDA-approved oral treatment for adults with C3G, to reduce proteinuria

Substantial proteinuria reduction at 6 months compared to placebo in adults with C3G who had never received a kidney transplant*:

-30% reduction with FABHALTA

+8% increase with placebo

The most common side effects of FABHALTA in adults include: headache; nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis); diarrhea; pain in the stomach (abdomen); infections (bacterial and viral); nausea; rash.

There is a risk of serious infections while taking FABHALTA. Because of this risk, FABHALTA is only available through a REMS program that requires vaccinations. See page 9 for more information on vaccinations. See page 11 for more on the FABHALTA REMS program.

*In a clinical study of adult patients with biopsy-confirmed C3G who had never received a kidney transplant. Safety and effectiveness of FABHALTA in patients with C3G following kidney transplant have not been established. Efficacy results were analyzed at 6 months in 74 adults. 38 patients took 200 mg FABHALTA twice daily and 36 patients took placebo (sugar pill) twice daily. All patients were on a stable dose of maximally tolerated blood pressure medications (ACEi/ARB) with or without other background therapies 90 days prior to the study and throughout the study. See page 5 for full Study Design details.

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; REMS, Risk Evaluation and Mitigation Strategy.

Approved Use

What is FABHALTA?

FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).

It is not known if FABHALTA is safe and effective in children with C3G.

Important Safety Information

What is the most important information I should know about FABHALTA?

FABHALTA is a medicine that affects part of your immune system and may lower your ability to fight infections.

- **FABHALTA increases your chance of getting serious infections caused by encapsulated bacteria,** including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and *Haemophilus influenzae* type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early.

Please see additional Important Safety Information throughout and on pages 12–13, and full Prescribing Information, including Boxed WARNING and Medication Guide.

Want to share your FABHALTA story? Help inspire and empower others with C3G by sharing your experiences.

Call 1-877-879-0245 (8 AM to 5 PM PST) or info@voices-of-inspiration.com

FABHALTA® (iptacopan) 200 mg capsules

NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080